It has also been reported that one-year IL-17 mAb therapy reduces the size of the lipid-rich necrotic core, a high-risk coronary plaque feature, as assessed by coronary computed tomography angiography, providing evidence that systemic treatment of psoriasis with IL-17 mAbs may be beneficial for CVDs treatment [50]. Here, IL17A is linked to psoriasis.